The PTAB has instituted IPR2016-01837, in which Hospira challenges Genentech’s U.S. Patent 7,807,799. The institution decision extends to all challenged claims, claims 1-3 and 5-11. According to the decision, the ‘799 patent relates to improved methods for conducting protein A affinity chromatography, and the specification includes an example using trastuzumab. Trastuzumab is marketed by Genentech under the trade-name Herceptin®, and is indicated for treating certain types of breast cancer.
This decision and other important documents related to IPRs on biologic patents are posted to our IPR tracker page.